GhanaTuberculosis profile
Population  2014 27 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 9.7 (4.4–17) 36 (16–64)
Mortality (HIV+TB only) 4.2 (2.3–6.5) 16 (8.8–24)
Prevalence  (includes HIV+TB) 75 (30–140) 282 (111–530)
Incidence  (includes HIV+TB) 44 (21–75) 165 (80–281)
Incidence (HIV+TB only) 11 (5.2–19) 42 (20–72)
         
Case detection, all forms (%) 33 (19–69)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 17 (4.4–30)
MDR-TB cases among notified pulmonary
TB cases
220 (39–400) 180 (46–310)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 7 682   441
Pulmonary, clinically diagnosed 5 364    
Extrapulmonary 1 181    
       
Total new and relapse 14 668    
Previously treated, excluding relapses 608    
Total cases notified 15 276    
Among 14 668 new and relapse cases:
713 (5%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 328 (4%) 1 471 (140%) 1 799
Laboratory-confirmed RR-/MDR-TB cases     93
Patients started on MDR-TB treatment ***     14
TB/HIV 2014 Number (%)
TB patients with known HIV status 11 830 (77)
HIV-positive TB patients 2 858 (24)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 1 910 (67)
HIV-positive TB patients on antiretroviral therapy (ART) 1 104 (39)
HIV-positive people screened for TB 49 343  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (85) 15 043
Previously treated cases, excluding relapse, registered in 2013 (77) 563
HIV-positive TB cases, all types, registered in 2013 (73) 2 737
RR-/MDR-TB cases started on second-line treatment in 2012 (100) 2
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 0.6
Drug susceptibility testing (per 5 million population) 0.6
Sites performing Xpert MTB/RIF 13
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 44
% Funded domestically 36%
% Funded internationally 29%
% Unfunded 36%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-27 Data: www.who.int/tb/data